Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
|
|
- Peregrine Alban Berry
- 5 years ago
- Views:
Transcription
1 Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France
2 MP: Standard of care until 2007 J Clin Oncol 1998;16: randomized trials, 6633 pts MP vs combination chemotherapy 1617 pts years 497 pts 75+ Response rate: CCT 60 vs 53% Survival: MP vs CCT identical MP: standard of care until 2007
3 Survival benefit MP +
4 IFM 99-06: Newly diagnosed MM patients years 3 MP arm (n = 196) Standard MP; 12 courses at 6-week intervals Newly diagnosed MM patients, age years (N = 447) 2 2 MPT arm (n = 125) MP arm + Thal at MTD but 400 mg/day, stopped at end of MP MEL100 arm (n = 126) Primary end-point: OS VAD 2; cyclophosphamide 3 g/m 2 + G-CSF + PBSC harvest (M 100 mg/m 2 + PBSC + G-CSF) 2 Facon T, et al. Lancet. 2007;370:
5 Progression-free patients (%) IFM 99-06: progression-free survival benefit with MPT Treatment PFS, months p value MP (n = 196) 17.8 ± 1.4 MPT (n = 125) 27.5 ± 2.1 < MEL100 (n = 126) 19.4 ± Median follow-up duration 51.5 (range ) months 20 0 MP MPT MEL Time from randomization (months) Facon T, et al. Lancet. 2007;370:
6 Patients (%) IFM : survival benefit Treatment OS, months p value MP (n = 196) 33.2 ± MPT (n = 125) 51.6 ± MEL100 (n = 126) 38.3 ± Median follow-up duration 51.5 (range ) months MP MPT MEL Time from randomization (months) Facon T, et al. Lancet. 2007;370:
7
8 IFM 01/01 Study protocol Newly diagnosed MM > 75 years 12 cycles MP every 6 weeks Melphalan 0.2 mg/kg/d Day 1-4 Prednisone 2 mg/kg/d Day 1-4 Double Blind Placebo 2 caps 50 mg/d 72 weeks Thalidomide 2 caps 50 mg/d 72 weeks Hulin C, et al, J Clin Oncol. 2009; 27:
9 Proportion of surviving patients IFM 01-01: Progression-free survival 1,0 0,8 0, vs 18.5 months, p = ,4 0,2 MP MP+Thalidomide 0, Months Hulin C, et al, J Clin Oncol. 2009; 27:
10 Proportion of surviving patients IFM 01-01: Overall survival 1,00 0,80 0,60 44 vs 29.1 months, p = ,40 0,20 MP MP+Thalidomide 0, Months Hulin C, et al, J Clin Oncol. 2009;27:
11 MP vs MPT: progression-free survival and overall survival Median PFS, months MP MPT GIMEMA 1,2 IFM IFM Nordic 5 HOVON p value < TTP < Median OS, months MP MPT p value NS NS NS *Event-free survival. Significant. In 5 of 5 studies, MPT was superior to MP in terms of PFS or TTP (or both) In 2 of 5 studies, MPT was superior to MP in terms of OS * Palumbo A, et al. Lancet. 2006;111: Palumbo A, et al. Blood. 2008;112: Facon T, et al. Lancet. 2007;370: Hulin C, et al. J Clin Oncol. 2009; in press. 5. Waage A, et al. Blood. 2007;110:[abstract 78]. 6. Wijermans P, et al. Blood. 2008;112:[abstract 241]; updated data presented at ASH, 2008.
12 MPT : Conclusions Five studies (GIMEMA, IFM 99-06, IFM 01-01, NMSG, HOVON) have shown that the use of thalidomide in combination with MP (MPT) improves response rates and TTP and/or PFS compared with MP The 2 IFM studies have shown that MPT improves OS compared with MP, extending OS by months MPT is a new standard of care for newly diagnosed elderly patients with myeloma. EMEA approved front-line MPT in elderly MM patients in April 2008.
13 The VMP schedule was based on the standard bortezomib monotherapy dosing schedule Mateos, M.-V. et al. Blood 2006;108:
14 Phase III study of VMP versus MP in previously untreated multiple myeloma 682 untreated MM patients ineligible for HDT-SCT from 151 centres in 22 countries R A N D O M I S A T I O N VMP (N = 344) Bortezomib 1.3 mg/m 2 on days: cycles 1 4: 1, 4, 8, 11, 22, 25, 29, and 32; cycles 5 9: 1, 8, 22, and 29 + melphalan 9 mg/m 2 and prednisone 60 mg/m 2 on days 1 4 MP (N = 338) Melphalan 9 mg/m 2 and prednisone 60 mg/m 2 on days week cycles 54 weeks treatment Stratification for baseline beta-2-microglobulin and albumin levels and region Primary end point TTP Secondary end points: CR rate, ORR, time to response, DOR, time to next therapy (TNT), OS, QoL (PRO)
15 Event-free patients (%) Patients (%) VISTA: time to progression and overall survival Time to progression Overall survival 100 VMP MP VMP: 24 months (83 events) MP: 16.6 months (146 events) HR 0.48, p < Median follow-up: 16.3 months VMP: not reached (45 deaths) MP: not reached (76 deaths) HR 0.61, p = Time (months) Time (months) OS at 3 years:72% in VMP group vs 69.5% in MP group San Miguel JF, et al. N Engl J Med. 2008;359: Mateos MV, J Clin Oncol 2010, April 5.
16 Matéos MV, J Clin Oncol 2010
17 Grade 3/4 adverse events (%) VMP (n=340) MP (n=337) Grade 3/4 Grade 3/4 Neutropenia 40% 38% Thrombocytopenia 37% 30% GI 20% 6% Peripheral neuropathy 14% 0% Fatigue 8% 2% Asthenia 8% 2% Pneumonia 7% 5% Herpes Zoster 3% 2%
18 VISTA MPV significantly prolongs survival and is superior for all pre-specified efficacy endpoints in the largest MP-based phase III study Rapid and durable responses with high CR rate (35%) Prolonged TTP, time to next therapy/treatment-free interval, and OS MPV data are consistently superior across all prognostic subgroups MPV was well tolerated, with patients on therapy for 46 weeks These results establish MPV as a new standard of care for MM patients not eligible for ASCT. EMEA and FDA approved frontline bortezomib for previously untreated MM patients in 2008.
19 Cheson BD & Rummel MJ. J Clin Oncol 2009
20 Pönisch et al, J Cancer Res Clin Oncol 2006;132: BP vs MP Prospective comparison Bendamustine-prednisolone vs melphalan prednisolone 131 pts CR rate, time to maximum response, time to treatment failure in favor of BP
21 Phase III: VMP vs VTP in newly diagnosed elderly patients with MM (PETHEMA/GEM study) 260 patients, multicenter Randomization step 1 Induction VMP vs VTP Randomization step 2 Maintenance VT vs VP VT vs VP Mateos et al. ASH 2009 (abstract 3); oral presentation
22 Phase III: VMP vs VTP in newly diagnosed elderly patients with MM VMP VTP One 6-week cycle Bortezomib twice weekly Melphalan Prednisone Bortezomib twice weekly Thalidomide Prednisone Five 5-week cycles Bortezomib once weekly Melphalan Prednisone Bortezomib once weekly Thalidomide Prednisone Mateos et al. ASH 2009 (abstract 3); oral presentation
23 Phase III: VMPT + VT vs VMP in elderly patients with newly diagnosed MM GIMEMA study Patients (n=511): >65 years old; median age 71 years Treatment VMPT VMP 9 x 5-week cycles Bortezomib Melphalan Prednisone 9 x 5-week cycles Bortezomib Melphalan Prednisone Thalidomide Maintenance: Bortezomib + Thalidomide No maintenance Palumbo et al. ASH 2009 (abstract 128); oral presentation
24 Phase I/II Melphalan, prednisone, and lenalidomide (MPR) treatment schedule Up to 9 cycles Median age, 71 (57-77) 54 patients Palumbo A, et al. J Clin Oncol. 2007;25:
25 Melphalan, prednisone, and lenalidomide (MPR) for newly diagnosed MM Response Patients, % CR 24 VGPR 24 PR 33 SD 19 Adverse events at MTD, grade 3 Patients, % Neutropenia 52 Thrombocytopenia 24 DVT 5 G-CSF support 43 Palumbo A, et al. J Clin Oncol. 2007;25:
26 Event-free patients (%) Patients (%) MPR MPR: median follow-up 14.6 ( ) months (N = 53) Event-free survival Overall survival Time (months) Time (months) Palumbo A, et al. J Clin Oncol. 2007;25:
27 MM-015: MPR vs MP for long-term control in newly diagnosed MM 51 centres in Europe, Australia, and Israel (N = 459) Patients with newly diagnosed, untreated MM who are not eligible for a transplant Double-blind treatment phase Up to 9 courses in the absence of PD or unacceptable adverse events R A N D O M I Z A T I O N Melphalan 0.18 mg/kg, days 1 4 Prednisone 2 mg/kg, days 1 4 Lenalidomide 10 mg/day p.o. days 1 21 Melphalan 0.18 mg/kg, days 1 4 Prednisone 2 mg/kg, days 1 4 Lenalidomide 10 mg/day p.o. days 1 21 Melphalan 0.18 mg/kg, days 1 4 Prednisone 2 mg/kg, days 1 4 Placebo days 1 21 Lenalidomide Placebo Placebo Primary end-point: progression-free survival Secondary end-points: OS, TTP, ORR, TTR, duration of response, and quality of life All patients will receive aspirin prophylaxis ( mg/day) TTR = time to response. Trial NCT Available from:
28 Patients without Event (%) Progression-Free Survival First Interim Analysis 50% Reduced Risk in PFS 100 Median PFS 75 MPR-R MP Not reached 13.0 months Median follow up: 9.4 mos HR % CI [0.330, 0.755] Logrank P< PFS Time (months) Palumbo et al, ASH
29 Patients without Event (%) Overall Survival % 1-year Overall Survival MPR-R MP 25 0 Total number of deaths: Palumbo et al, ASH OS time (months) 29
30 MRC Myeloma IX: non-intensive pathway Older, less fit patients (age > 65 years) Clodronate Randomization vs Zoledronic acid Respon se Patients, % CTD MP MP vs CTDa CR Randomization VGPR Thalidomide vs No thalidomide PR CTD : cyclophosphamide 500 mg orally, once weekly; thalidomide 200 mg/day; dexamethasone 20 mg, days 1 4 and of a 28-day cycle Morgan GJ, et al. Blood. 2007;110:[abstract 3593]. Morgan GJ, et al. Blood. 2008;112:[abstract 245].
31 ECOG-E4A03: Len + standard- or low-dose Dex in newly diagnosed MM Phase III, randomized study in newly diagnosed MM (N = 445) Four courses, every 28 days R A N D O M I Z A T I O N Arm 1 Lenalidomide 25 mg/day p.o., days 1 21 Standard-dose dexamethasone 40 mg/day p.o., days 1 4, 9 12, Dexamethasone 480 mg per cycle (n = 223) Arm 2 Lenalidomide 25 mg/day p.o., days 1 21 Lower-dose dexamethasone 40 mg/day p.o., days 1, 8, 15, 22 Dexamethasone 160 mg per cycle (n = 222) CR or PR Less than PR Thal + Dex 4 cycles Patients eligible for SCT can proceed to SCT CR or PR or SD Rajkumar SV, et al. Lancet Oncol 2010;11:29-37.
32 ECOG-E4A03: adverse events Grade 3 or 4 adverse event Len + high-dose Dex, % (n = 223) Len + low-dose Dex, % (n = 220) p value Infection or pneumonia DVT or PE < Neuropathy Cardiac ischaemia Any non-hematological AEs (Grade 3) <0.001 AEs (Grade 4) Early deaths (< 4 mnth)
33 Rajkumar SV, et al. Lancet Oncol 2010;11:29-37.
34 ECOG-E4A03: efficacy of Len plus low-dose Dex in newly diagnosed MM Primary Rd beyond 4 cycles Patients, % (n = 142) CR + PR 89 CR (IF ) 22 CR + VGPR 56 2-Year survival 93
35 ECOG-E4A03: Len + high-dose Dex vs Len plus low-dose Dex in newly diagnosed MM Survival rate in patients 65 years old Patients, n 2-Year survival probability (95% CI) RD ( ) Rd ( ) p = 0.009
36 Novel combinations as primary therapy Best choice? MPT MPV approved BP, soon MPV once weekly MPR CTD Rev-low dose dex
37 Novel agents as primary treatment Study n Median age, years CR, % CR + VGPR, % CR + PR, % EFS or TTP MPT IFM MPT MPT vs MP MPV VISTA MPR MPR Rd ECOG-E4A Median 28 months Median 22 months Median 24 months 87% at 16 months Median 23 months CTD MRC Myeloma IX NR
38 ECOG-E1A06: MPT vs MPR in transplantineligible patients with newly diagnosed MM R A N D O M I Z A T I O N MPT MPR CR, PR, or stable Progression any time Continue therapy until progression or adverse event Off therapy Trial NCT Available at:
39 HOVON-87: MPT vs MPR in transplantineligible patients with newly diagnosed MM Inclusion criteria Previously untreated MM Age 65 years or not a candidate for transplantation WHO-PS: 0 3 in patients aged < 75 years and 0 2 in patients aged 75 years Melphalan 0.18 mg/kg/day, days 1 4, every 28 days Prednisone 2.0 mg/kg/day, days 1 4, every 28 days Lenalidomide 10 mg/day, days 1 21, every 28 days Melphalan 0.18 mg/kg/day, days 1 4, every 28 days Prednisone 2.0 mg/kg/day, days 1 4, every 28 days Thalidomide 200 mg/day, daily through 28-day cycle Nine 4-week cycles followed by lenalidomide 10 mg/day maintenance until disease progression Nine 4-week cycles followed by thalidomide 100 mg/day maintenance until disease progression Primary end-point: progression-free survival
40 FIRST: lenalidomide + low-dose Dex vs MPT (IFM 07-01) Inclusion criteria Previously untreated MM Age 65 years or not a candidate for transplantation No neuropathy of grade > 2 CL Cr > 30 ml/min N = 1,590 Centres in EU, Switzerland, USA, and Canada Lenalidomide 25 mg/day, days 1 21; every 28 days Dexamethasone* 40 mg/day, days 1, 8, 15, 22; every 28 days Lenalidomide 25 mg/day, days 1 21; every 28 days Dexamethasone* 40 mg/day, days 1, 8, 15, 22; every 28 days Melphalan* 0.25 mg/kg/day, days 1 4, every 42 days Prednisone 2.0 mg/kg/day, days 1 4, every 42 days Thalidomide* 200 mg/day, daily through 42-day cycle * In patients older than 75 years: dexamethasone 20 mg/day, melphalan 0.20 mg/kg/day, thalidomide 100 mg/day. Primary end-point: progression-free survival Until PD Eighteen 4-week cycles Twelve 6-week cycles
41 PAD - MEL100 LP L in elderly patients (65 75 years) PAD PBSC Mobilisation (Cyclophosphamide + G-CSF) MEL 100 ASCT LP L 4 cycles 2 cycles 2 cycles 4 cycles PAD = bortezomib + pegylated-doxorubicin + dexamethasone MEL 100 = melphalan 100 mg/m² LP = lenalidomide + prednisone L= lenalidomide Palumbo A, et al.j Clin Oncol 2010;28:
42
43 Conclusions Adding novel agents to MP improves the response rate and quality of response adding oral thalidomide to MP prolonged PFS in 5 and survival in 2 of 5 phase III trials combination approved adding injectable bortezomib to MP prolonged PFS and survival in one phase III trial combination approved BP in patients with neuropathy MPR shows promising results CTD is a well-tolerated oral regimen that has shown a high response rate in a large MRC phase III trial Lenalidomide plus low-dose dexamethasone Is currently being compared with MPT Role of maintenance therapy?? Role of ASCT with novel agents??
Management of Multiple
Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationMichel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationChristine Chen Princess Margaret Cancer Centre September 2013
Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationMULTIPLE MYELOMA AFTER AGE OF 80 YEARS
MULTIPLE MYELOMA AFTER AGE OF 80 YEARS C. Hulin CHU Nancy, France Intergroupe Francophone du Myelome (IFM) Epidemiology SEER Program between 1990-2004: 17 330 MM cases, 51% 70 y and 20% 80 y. Brenner et
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationTiming of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationConsolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationTransplant in MM patients: Early versus late. Mario Boccadoro. Barcelona
Transplant in MM patients: Early versus late Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Transplant in MM patients: Early versus
More informationMultiple Myeloma: Miami, FL Current Treatment Paradigms and Future Directions December 18, 2009
Welcome to Master Class for Oncologists Miami, FL December 18, 29 Session 5: 11: AM - 11:45 AM Multiple Myeloma: Current Treatment Paradigms and Future Directions Speaker: Kenneth C. Anderson, MD Chief,
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationMultiple Myeloma in the Elderly: When to Treat, When to Go to Transplant
Multiple Myeloma in the Elderly: When to Treat, When to Go to Transplant Review Article [1] October 15, 2010 By Jean-luc Harousseau, MD [2] Until recently, standard treatment of multiple myeloma (MM) in
More informationInternational Myeloma Foundation Patient and Family Seminar
International Myeloma Foundation Patient and Family Seminar Vienna, Austria May 6 th, 2006 New Development in Diagnosis & Treatments Brian G.M. Durie, M.D., Chairman International Myeloma Foundation What
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationAutologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy
Autologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy Donna E. Reece, M.D. Princess Margaret Hospital Toronto, ON CANADA 10 December 2011 ASCT in Myeloma..
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationTreatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice Friday, December 2, 2016 San Diego, California This program is supported by educational grants from
More informationOncology Highlights ASCO 2011 MULTIPLE MYELOMA
Oncology Highlights ASCO 211 MULTIPLE MYELOMA July 211 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist, Mayo Clinic Arizona Disclosures
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Bortezomib as first line induction prior to melphalan and autologous stem cell transplantation (ASCT) in untreated symptomatic multiple myeloma patients suitable
More informationShould we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain
Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat some patients with Stage I MM? Len-dex is a promising and atractive option
More informationPlasma cells in bone marrow. Treatment of Multiple Myeloma Novel Approaches. Approach to Progressive MM. Approach to Initial Therapy
Treatment of Multiple Myeloma ovel Approaches Plasma cells in bone marrow Donna E. Reece, M.D. Princess Margaret Hospital Toronto, 21 ctober 25 Adhesion Molecules and Growth Factors in Multiple Myeloma
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationVI. Autologous stem cell transplantation and maintenance therapy
Hematological Oncology Hematol Oncol 2013; 31 (Suppl. 1): 42 46 Published online in Wiley Online Library (wileyonlinelibrary.com).2066 Supplement Article VI. Autologous stem cell transplantation and maintenance
More informationRole of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape
Role of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape Simrit Parmar, MD MDACC Houston, TX, USA Why Transplant in the Era of Novel Therapy? Safe (TRM
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More informationMyeloma and renal failure Future directions. Karthik Ramasamy
Myeloma and renal failure Future directions Karthik Ramasamy Overview Historical perspective & Background Drug interventions & trials OPTIMAL Trial Future directions Burden of disease Upto 40% of newly
More informationMultiple Myeloma: Diagnosis and Primary Treatment
Multiple Myeloma: Diagnosis and Primary Treatment George Somlo, MD City of Hope Comprehensive Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Educational Objectives Discuss considerations
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationMaintenance therapy after autologous transplantation
Maintenance therapy after autologous transplantation Sonja Zweegman MD PhD Department of Hematology Amsterdam The Netherlands Disclosures Research funding from Celgene, Takeda and Janssen Participation
More informationOvercoming Current Challenges in the Management of De Novo and Relapsed/Refractory Multiple Myeloma
Overcoming Current Challenges in the Management of De Novo and Relapsed/Refractory Multiple Myeloma George Somlo M.D. City of Hope Comprehensive Cancer Center The Cause 1 Myeloma: Clinical Features Bone
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationMultiple Myeloma: Approach to the Elderly
Multiple Myeloma: Approach to the Elderly Peter Anglin MD, FRCPC, MBA Stronach Regional Cancer Centre Newmarket, ON PMH Myeloma Day May 12, 2017 Peter Anglin MD Disclosures Speakers Bureau Advisory Boards
More informationManaging Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study
Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient Case Study 2 2011 Newly Diagnosed Patient The patient is a 61-year-old Caucasian female History of high blood pressure
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationDr Shankara Paneesha. ASH Highlights Department of Haematology & Stem cell Transplantation
ASH Highlights 2015 Themes of ASH 2015 Novel therapies - Myeloma AML Lymphoma Pd-L1 & PD-l inhibitors Emerging concepts in biology HIF-1a pathway Cautionary tales ASH Choosing Wisely list IFM/DFCI
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationBest of ASH 2017 DR. BRIAN DURIE. Brian GM Durie, MD Thursday, January 11, 2018
Best of ASH 2017 DR. BRIAN DURIE Brian GM Durie, MD Thursday, January 11, 2018 1 ASH Overview 2017 Total myeloma abstracts: 981 Important/Interesting: oral ~40 posters ~60 100 2 Which abstracts impact
More informationH. Lee Moffitt Cancer Center and Research Institute, University of California, San Francisco & Tisch Cancer Institute, Mount Sinai School of Medicine
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study Rachid Baz, Thomas
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More informationDisclosures for Alessandra Larocca, MD
Disclosures for Alessandra Larocca, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria No relevant conflicts of interest to declare No relevant conflicts of interest
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationMethods: Studies included in the analysis
Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,
More informationProteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor
More informationNovel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
More informationExperience with bortezomib (Velcade) in multiple myeloma. Peter Černelč Clinical center Ljubljana Department of Haematology
Experience with bortezomib (Velcade) in multiple myeloma Peter Černelč Clinical center Ljubljana Department of Haematology Our experience with bortezomib (Velcade) in multiple myeloma 1. Our first experience
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationWho should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
More informationStem Cell Transplant for Myeloma: The New Landscape
Stem Cell Transplant for Myeloma: The New Landscape Sergio A. Giralt, MD Chief, Adult Bone Marrow Transplant Service Division of Hematologic Oncology Department of Medicine Memorial Sloan-Kettering Cancer
More informationDRAFT FOR PUBLIC CONSULTATION
SEE MYELOMA ELIGIBLE egfr < 30ml/min Multiple myeloma despite correction of hypercalcaemia and dexamethasone? Yes Transplant eligible? Yes SEE MYELOMA- RENAL SEE MYELOMA INELIGIBLE KEY Click to move to
More informationAperTO - Archivio Istituzionale Open Access dell'università di Torino
AperTO - Archivio Istituzionale Open Access dell'università di Torino Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis
More informationIs Myeloma Curable in 2012?
Is Myeloma Curable in 2012? YES Cure is living long enough to die of another cause April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist,
More informationMYBORPRE. Protocol Code. Lymphoma, Leukemia/BMT. Tumour Group. Dr. Kevin Song. Contact Physician
BC Cancer Protocol Summary for the Treatment of Multiple Myeloma Using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant Protocol Code Tumour Group Contact
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationUpdates in Multiple Myeloma: 12 months in 10 minutes
Updates in Multiple Myeloma: 12 months in 10 minutes Aaron Rosenberg MD, MS Assistant Prof. Medicine UC Davis Comprehensive Cancer Center Division of Hematology and Oncology Outline Standard of care for
More informationPomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. Lacy MQ et al. J Clin Oncol 2009;27(30):
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma Lacy MQ et al. J Clin Oncol 2009;27(30):5008-14. Introduction A curative therapy for multiple myeloma (MM) does
More informationOncologist. The. Academia Pharma Intersect: Myelomas. Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
The Oncologist Academia Pharma Intersect: Myelomas Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective HEINZ LUDWIG, a MERAL BEKSAC, b JOAN BLADÉ, c MARIO BOCCADORO,
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Lines of Therapy: Updated Analysis of CASTOR Maria-Victoria
More informationKalyan Nadiminti, MBBS 4/13/18
A Single Autologous Stem Cell Transplant (ASCT) followed by two years of post-transplant therapy is safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective
More informationMaking Sense of Myeloma Treatment Advances
Making Sense of Myeloma Treatment Advances Webinar 1, May 17, 217 Updates From the 16th International Myeloma Workshop and the American Association for Cancer Research 217 Annual Meeting Speakers Moderator:
More informationNovel Therapies for the Treatment of Newly Diagnosed Multiple Myeloma
Novel Therapies for the Treatment of Newly Diagnosed Shaji K. Kumar, MD Professor of Medicine Mayo Clinic College of Medicine Consultant, Division of Hematology Medical Director, Cancer Clinical Research
More informationMYELOMA MAINTENANCE BEST PRACTICES:
MYELOMA MAINTENANCE BEST PRACTICES: POST THERAPY & POST TRANSPLANT Aric Hall, MD Assistant Professor University of Wisconsin Hospital and Clinics INTRODUCTION MYELOMA Clonal plasma cell malignancy leading
More information